Organogenesis (NASDAQ:ORGO) Trading 3.5% Higher - Here's Why

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report)'s stock price traded up 3.5% during trading on Tuesday . The company traded as high as $5.08 and last traded at $5.15. 148,169 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 1,070,616 shares. The stock had previously closed at $4.97.

Analyst Ratings Changes

Separately, Morgan Stanley lifted their price objective on Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a research report on Wednesday, March 5th.

Organogenesis Stock Performance

The stock has a 50 day simple moving average of $4.04 and a 200 day simple moving average of $3.50. The company has a market cap of $618.92 million, a price-to-earnings ratio of -81.33 and a beta of 1.66. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21.

Insider Buying and Selling

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the sale, the director now directly owns 166,879 shares of the company's stock, valued at $851,082.90. The trade was a 13.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 36.90% of the company's stock.

Remove Ads

Institutional Trading of Organogenesis

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in Organogenesis in the fourth quarter valued at about $38,000. Captrust Financial Advisors bought a new position in shares of Organogenesis during the third quarter valued at approximately $36,000. Intech Investment Management LLC bought a new position in shares of Organogenesis during the third quarter valued at approximately $43,000. Palumbo Wealth Management LLC bought a new position in shares of Organogenesis during the fourth quarter valued at approximately $65,000. Finally, ProShare Advisors LLC grew its holdings in shares of Organogenesis by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock valued at $65,000 after purchasing an additional 6,689 shares during the last quarter. 49.57% of the stock is owned by institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.